Key Highlights
- Revenue was USD 895.31 million against an estimate of USD 877.76 million and USD 851.57 million in the prior-year quarter.
- EPS of USD 0.60 compares with an estimate of USD 0.46, while GAAP diluted EPS was USD 0.38.
- A USD 15.0 million Sandoval litigation settlement was paid during the quarter, and government investigation costs were USD 18.27 million.
- Same Facility Revenue growth was 5.2%, with admissions growth of 6.6% and patient days growth of 1.1%.
Acadia Healthcare Company, Inc. (NASDAQ:ACHC) reported third quarter legal and investigation items alongside its operating numbers. The company paid USD 15.0 million to resolve all remaining claims in the Sandoval wrongful death litigation, recorded USD 18.27 million of government investigation costs, and continues to cooperate with a DOJ Criminal Division inquiry and an SEC inquiry. Revenue was USD 895.31 million.
How the Legal Items Fit the Quarter
The Sandoval matter followed a Jury judgment that was affirmed in substantial part in April 2026. The company signed a settlement on May 31 with no admission of liability, and the USD 15.0 million payment was made in the third quarter.
Separately, the quarter shows a legal settlements gain of USD 7.15 million, which the company tied mainly to insurance proceeds received in excess of attorneys' fees and payments to plaintiffs' counsel in settled derivative cases. Transaction, legal and other costs were USD 23.74 million against USD 42.92 million a year earlier, with government investigations accounting for USD 18.27 million against USD 38.74 million. The federal inquiries began with grand jury subpoenas in September 2024 on acute care admissions, length of stay and billing practices. The company said it has made no findings or conclusions from its internal investigation and cannot estimate any liability.
Results Around the Events
Revenue rose to USD 895.31 million from USD 851.57 million. Same facility revenue grew 5.2%, built on revenue per patient day growth of 4.0%, patient days growth of 1.1% and admissions growth of 6.6%. Average length of stay changed by negative 5.1%.
Salaries, wages and benefits were USD 490.27 million, or 54.8% of revenue, against 54.3%, with the company citing new facility openings and routine annual wage increases. Professional fees were USD 58.66 million against USD 51.48 million. Depreciation and amortization was USD 53.13 million and interest expense was USD 37.28 million. Income before income taxes was USD 56.47 million, and the provision for income taxes was USD 17.82 million against USD 1.67 million. Net Income attributable to the company was USD 34.49 million, or USD 0.38 per diluted share, against USD 36.25 million, or USD 0.40.
Cash, Debt and Capital Position
Cash provided by Operating Activities was USD 321.5 million over nine months, against USD 218.2 million, which the company linked to insurance proceeds from the 2019 securities litigation and state supplemental payment programs. Capital expenditures were USD 165.9 million, split into USD 71.1 million of routine spending and USD 94.8 million of expansion spending.
Cash and cash equivalents were USD 163.3 million at September 30 against USD 133.2 million at year end. Debt includes a USD 617.5 million Term Loan A, USD 274.0 million drawn on the revolver, and senior notes of USD 450.0 million due 2028, USD 475.0 million due 2029 and USD 550.0 million due 2033. There were no share repurchases in the quarter, and USD 250.0 million of authorization remains.
Quarter in Numbers
Revenue of USD 895.31 million sits alongside net income attributable to the company of USD 34.49 million, cash of USD 163.3 million and long-term debt of USD 2.32 billion. The company operated 280 facilities with about 12,800 beds in 40 states and Puerto Rico, and added 542 beds in nine months, including joint venture openings with Tufts Medicine, Orlando Health and Methodist Jennie Edmundson. Dated items the company named include the requirement that states implement Medicaid work and community engagement rules by December 31, 2026, and the September 2024 subpoenas that remain open.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...